Breaking Finance News

A statement released earlier today by Roth Capital about Fortress Biotech (NASDAQ:FBIO) bumps the target price to $9.00

Having a price of $2.97, Fortress Biotech (NASDAQ:FBIO) traded 1.68% higher on the day. With the last close down 1.58% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Fortress Biotech has recorded a 50-day average of $2.76 and a two hundred day average of $2.97. Volume of trade was down over the average, with 24,498 shares of FBIO changing hands under the typical 89,344

Stating a potential upside of 2.03%, Roth Capital upped the price target of Fortress Biotech (NASDAQ:FBIO) to $9.00

On 9/20/2016, Zacks Investment Research released a statement on Fortress Biotech (NASDAQ:FBIO) upped the target price from $0.00 to $3.00 that suggested an upside of 0.09%.

Performance Chart

Fortress Biotech (NASDAQ:FBIO)

With a total market value of $0, Fortress Biotech has with a one year low of $2.10 and a one year high of $4.66 .

More About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *